Atrys Health, S.A. (BME:ATRY)

Market Cap	209.88M +2.8%
Revenue (ttm)	144.31M +7.0%
Net Income	-100.30M
EPS	-1.32
Shares Out	75.91M
PE Ratio	n/a
Forward PE	47.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,763
Open	2.845
Previous Close	2.810
Day's Range	2.765 - 2.870
52-Week Range	2.480 - 3.590
Beta	0.56
Analysts	Strong Buy
Price Target	4.83 (+74.68%)
Earnings Date	Jun 22, 2026

About Atrys Health

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 758
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ATRY

Financial Performance

In 2025, Atrys Health's revenue was 144.31 million, an increase of 7.00% compared to the previous year's 134.88 million. Losses were -100.30 million, 215.7% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for ATRY stock is "Strong Buy." The 12-month stock price target is €4.83, which is an increase of 74.68% from the latest price.

Price Target

€4.83

(74.68% upside)

Analyst Consensus: Strong Buy